Affiliations Chengde Nursing Vocational College, Department of Medical Technology, Chengde, 067000, China.
Cell Mol Biol (Noisy-le-grand). 2023 May 31;69(5):119-125. doi: 10.14715/cmb/2023.69.5.19.
The objective of this study was to observe the effect of recombinant human thrombopoietin on IL-2, IL-4 and platelet parameters in thrombocytopenic purpura. For this purpose, a convenient sampling method was used to select 84 patients with thrombocytopenic purpura who visited the hospital from January 2018 to December 2022. The patients were divided into the norm group and rhTPO group with 42 cases each by random number table. The norm group was treated with routine treatment, while the rhTPO group was treated with recombinant thrombopoietin based on routine treatment. The changes in IL-2, IL-4, platelet parameters, immune recovery and treatment efficiency of the two groups were compared before and after treatment. Findings suggested that the levels of IL-2 and IL-4 in both groups decreased after treatment compared with those before treatment. However, the level of IL-2 in the rhTPO group after treatment was lower than that in the norm group, and the level of IL-4 in the rhTPO group after treatment was higher than that in the norm group (P<0.05). The levels of platelet parameters PLT and PCT in the two groups after treatment were higher than those before treatment, but the levels of PLT and PCT in the rhTPO group after treatment were higher than those in the norm group (P<0.05). The PLT of the rhTPO group was (69.57±6.73)×109/L after 7 days of treatment, which was higher than that in the norm group (62.05 ± 8.52)×109/L (P<0.05). The levels of PDW and MPV in the two groups after treatment decreased compared with those before treatment, but the levels of PDW and MPV in the rhTPO group after treatment were lower than those in the norm group (P<0.05). The overall immune recovery and treatment effectiveness of the rhTPO group were significantly better than those of the norm group. In summary, recombinant human thrombopoietin used in patients with thrombocytopenic purpura can maintain the balance between T cell activation and inhibition homeostasis, and promote faster recovery of platelet parameters.
本研究旨在观察重组人血小板生成素对特发性血小板减少性紫癜患者白细胞介素-2（IL-2）、白细胞介素-4（IL-4）及血小板参数的影响。为此，采用便利抽样法选取 2018 年 1 月至 2022 年 12 月在我院就诊的 84 例特发性血小板减少性紫癜患者，采用随机数字表法将患者分为常规组和 rhTPO 组，各 42 例。常规组给予常规治疗，rhTPO 组在常规治疗基础上给予重组人血小板生成素治疗。比较两组患者治疗前后 IL-2、IL-4、血小板参数、免疫恢复及治疗效果的变化。结果显示，两组患者治疗后 IL-2、IL-4 水平均较治疗前降低，但 rhTPO 组治疗后 IL-2 水平低于常规组，IL-4 水平高于常规组（P<0.05）。两组患者治疗后血小板参数 PLT、PCT 水平均高于治疗前，且 rhTPO 组治疗后 PLT、PCT 水平高于常规组（P<0.05）。rhTPO 组治疗后 7 天 PLT 为（69.57±6.73）×109/L，高于常规组的（62.05 ± 8.52）×109/L（P<0.05）。两组患者治疗后 PDW、MPV 水平均较治疗前降低，但 rhTPO 组治疗后 PDW、MPV 水平低于常规组（P<0.05）。rhTPO 组患者整体免疫恢复和治疗有效率均显著优于常规组。综上所述，rhTPO 用于特发性血小板减少性紫癜患者可维持 T 细胞激活和抑制平衡，促进血小板参数更快恢复。
